SI20026B - Heptapeptidni analogi - antagonisti oksitocina - Google Patents

Heptapeptidni analogi - antagonisti oksitocina Download PDF

Info

Publication number
SI20026B
SI20026B SI9720076A SI9720076A SI20026B SI 20026 B SI20026 B SI 20026B SI 9720076 A SI9720076 A SI 9720076A SI 9720076 A SI9720076 A SI 9720076A SI 20026 B SI20026 B SI 20026B
Authority
SI
Slovenia
Prior art keywords
abu
asn
ile
mpa
ch2oh
Prior art date
Application number
SI9720076A
Other languages
English (en)
Slovenian (sl)
Other versions
SI20026A (sl
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of SI20026A publication Critical patent/SI20026A/sl
Publication of SI20026B publication Critical patent/SI20026B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI9720076A 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina SI20026B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (fr) 1996-11-26 1997-11-21 Analogues d'heptapeptide oxytocine

Publications (2)

Publication Number Publication Date
SI20026A SI20026A (sl) 2000-02-29
SI20026B true SI20026B (sl) 2000-06-30

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720076A SI20026B (sl) 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina

Country Status (35)

Country Link
US (1) US6143722A (fr)
EP (1) EP0938496B1 (fr)
JP (1) JP3405460B2 (fr)
KR (1) KR100463132B1 (fr)
CN (1) CN1129606C (fr)
AR (1) AR008531A1 (fr)
AT (1) ATE242264T1 (fr)
AU (1) AU713424B2 (fr)
BR (1) BR9713366B1 (fr)
CA (1) CA2272990C (fr)
CZ (1) CZ299532B6 (fr)
DE (1) DE69722651T2 (fr)
DK (1) DK0938496T3 (fr)
EE (1) EE03832B1 (fr)
ES (1) ES2203823T3 (fr)
HK (1) HK1022481A1 (fr)
HR (1) HRP970630B1 (fr)
HU (1) HU228568B1 (fr)
IL (1) IL129519A (fr)
LT (1) LT4650B (fr)
LV (1) LV12350B (fr)
MY (1) MY125555A (fr)
NO (1) NO321380B1 (fr)
NZ (1) NZ336445A (fr)
PL (1) PL189292B1 (fr)
PT (1) PT938496E (fr)
RO (1) RO120772B1 (fr)
RU (1) RU2180668C2 (fr)
SE (1) SE9604341D0 (fr)
SI (1) SI20026B (fr)
SK (1) SK283800B6 (fr)
TR (1) TR199901028T2 (fr)
UA (1) UA54459C2 (fr)
WO (1) WO1998023636A1 (fr)
ZA (1) ZA9710518B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
WO2003072597A1 (fr) * 2002-02-27 2003-09-04 Ferring Bv Intermediaires et procedes destines a fabriquer des analogues d'oxytocine heptapeptide
WO2003093816A2 (fr) * 2002-05-02 2003-11-13 Bayer Healtchare Ag Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
DK1530967T3 (da) * 2003-11-13 2006-07-03 Ferring Bv Blisterpakning og dertil hörende fast dosisform
EP1555029A1 (fr) 2004-01-19 2005-07-20 Ferring B.V. Utilisation de substances à activité oxytocique pour la préparation de médicaments destinés au traitement de l'hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
CN101983205B (zh) * 2008-03-31 2015-08-19 辉凌公司 催产素类似物
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
EP3225249B1 (fr) 2008-05-21 2018-11-07 Ferring B.V. Desmopressine orodispersible augmentant la période initiale de sommeil non perturbé par la nycturie
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
EP2593140A2 (fr) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Procédé d'augmentation de l'effet d'une forme activée-potentialisée d'un anticorps
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
DK2684888T3 (da) 2011-03-09 2019-08-19 Jitsubo Co Ltd Nye tværbundne peptider indeholdende ikke-peptid-tværbundet struktur, fremgangsmåde til syntetisering af tværbundne peptider og ny organisk forbindelse anvendt i fremgangsmåden
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
AU2016335061B2 (en) 2015-10-06 2021-02-25 Ferring B.V. New methods for making Barusiban and its intermediates
RS63285B1 (sr) 2016-01-04 2022-06-30 Merck Serono Sa L-valinat hidroksipropil tiazolidin karboksamidnog derivata, njegova so i njegov kristalni oblik
UA127283C2 (uk) 2016-07-21 2023-07-12 Обсева С.А. Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню
EP4025207A1 (fr) 2019-09-03 2022-07-13 ObsEva S.A. Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches
WO2021160597A1 (fr) 2020-02-10 2021-08-19 ObsEva S.A. Biomarqueurs pour une thérapie par antagoniste du récepteur de l'oxytocine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (fr) * 1990-02-27 1991-08-28 Mark G. Bock Antagonistes de l'oxytocine, a base d'hexapeptide cyclique
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE503085C2 (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
PL189292B1 (pl) 2005-07-29
SI20026A (sl) 2000-02-29
NO992532D0 (no) 1999-05-26
CN1129606C (zh) 2003-12-03
SE9604341D0 (sv) 1996-11-26
RU2180668C2 (ru) 2002-03-20
BR9713366B1 (pt) 2010-05-18
HUP0000577A2 (hu) 2000-11-28
CZ183299A3 (cs) 2000-05-17
CA2272990A1 (fr) 1998-06-04
EP0938496B1 (fr) 2003-06-04
CN1238781A (zh) 1999-12-15
WO1998023636A1 (fr) 1998-06-04
NO992532L (no) 1999-05-26
KR100463132B1 (ko) 2004-12-23
TR199901028T2 (xx) 1999-07-21
HRP970630A2 (en) 1998-10-31
IL129519A0 (en) 2000-02-29
LT4650B (lt) 2000-04-25
KR20000069045A (ko) 2000-11-25
EE9900210A (et) 1999-12-15
SK70499A3 (en) 2000-10-09
ES2203823T3 (es) 2004-04-16
AU5142998A (en) 1998-06-22
CZ299532B6 (cs) 2008-08-27
DK0938496T3 (da) 2003-10-06
LT99052A (en) 2000-01-25
HU228568B1 (en) 2013-04-29
EP0938496A1 (fr) 1999-09-01
PT938496E (pt) 2003-10-31
ZA9710518B (en) 1998-06-10
LV12350A (lv) 1999-09-20
HRP970630B1 (en) 2002-04-30
EE03832B1 (et) 2002-08-15
RO120772B1 (ro) 2006-07-28
US6143722A (en) 2000-11-07
BR9713366A (pt) 2000-01-25
IL129519A (en) 2004-09-27
ATE242264T1 (de) 2003-06-15
AU713424B2 (en) 1999-12-02
NO321380B1 (no) 2006-05-02
DE69722651D1 (en) 2003-07-10
HK1022481A1 (en) 2000-08-11
HUP0000577A3 (en) 2001-02-28
LV12350B (en) 1999-11-20
CA2272990C (fr) 2002-11-19
DE69722651T2 (de) 2004-04-08
JP3405460B2 (ja) 2003-05-12
MY125555A (en) 2006-08-30
NZ336445A (en) 2000-06-23
SK283800B6 (sk) 2004-02-03
AR008531A1 (es) 2000-01-19
UA54459C2 (uk) 2003-03-17
JP2000507617A (ja) 2000-06-20

Similar Documents

Publication Publication Date Title
SI20026B (sl) Heptapeptidni analogi - antagonisti oksitocina
RU99113364A (ru) Гептапептидные аналоги окситоцина
AU669856B2 (en) Compositions and methods for the sublingual or buccal administration of therapeutic agents
ES2589915T3 (es) Conjugados de GABA y métodos de utilización de los mismos
KR970042553A (ko) 캠프토테신 유도체
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
DE69912952D1 (en) Cyclosporine
SI2068907T1 (en) Pegylated sugars and glycopeptides are associated with glycerol
EP2130548A3 (fr) Peptides de libération d'hormone de croissance
RU2000100369A (ru) Аналоги пептида лг-рф, их применение и содержащие их фармацевтические композиции
DE69533399T2 (de) Zyklische hexapeptid somatostatin analoga
WO2001052894A3 (fr) Compositions peptidiques cycliques pouvant etre administrees par voie nasale
CA2097192A1 (fr) Antagonistes de la bombesine
JP2005508842A5 (fr)
SI9420001B (sl) Polipeptidni antagonisti bombezina
JP2019523260A5 (fr)
WO2006094725A1 (fr) Chelateurs pour des conjugués radioactivement marqués comprenant une chaîne latérale stabilisante
CA1335622C (fr) Analogues de la bradykinine comprenant une liaison non peptidique
WO2005018657A3 (fr) Analogues de gonadoliberine (gn-rh) non mammaliens et leur utilisation dans la regulation de la fertilite et de la gestation
WO2005019457A3 (fr) Analogues de la gnrh non mammiferes et leurs applications dans la regulation de la fertilite et de la grossesse
JP2006505556A5 (fr)
EP1700608A1 (fr) Agents chélatants comportant une chaîne latérale stabilisante pour des conjugués radiomarqués
AR029930A1 (es) Peptidos analogos de la sustancia p, procesos de sintesis de los mismos, composiciones y el uso de dichos peptidos para la manufactura de un medicamento para el tratamiento de cancer
CN1126999A (zh) 具有催产素拮抗剂活性的肽类化合物
EP0507484A1 (fr) Composition pharmaceutique à base d'aureobasidine

Legal Events

Date Code Title Description
IF Valid on the event date